Sera Prognostics, Inc. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2008

Location

Salt Lake City UT US

Primary Industry

Medical Devices & Equipment

About

Based in Utah, US, Sera Prognostics, Inc. was founded in 2008 by co-founders Dennis Farrar, Sean Esplin, and Steven Graves. Dr. Critchfield became the CEO of the company in November 2011. As of 2021, Sera Prognostics has 74 employees. In February 2021, Sera Prognostics raised USD 100.3 million in series E funding, and in July 2021, Sera Prognostics, Inc. raised USD 75 million in an IPO, selling 4.69 million shares at USD 16 per share on the NASDAQ. Sera Prognostics, Inc. provides the PreTRM® Test, a pregnancy testing kit that predicts early preterm birth risk of pregnancy complications and helps pregnant women and doctors to understand the potential pregnancy risk. The firm's platform uses proprietary biomarkers that are predictive of preterm birth, preeclampsia, and other pregnancy complications. Sera Prognostics, Inc. plans to use its Series E funding in April 2021 to continue commercializing its PreTRM® testing, accelerate the development of its pipeline of biomarker tests to predict other major conditions of pregnancy, and develop greater testing capacity.

Current Investors

Domain Associates, InterWest Partners, Catalyst Health Ventures

Request a demo to show more

Primary Industry

Medical Devices & Equipment

Sub Industries

Bioinformatics, Diagnostic, Medical & Imaging Laboratories, Diagnostic Equipment

Website

www.seraprognostics.com

Verticals

HealthTech

Company Stage

Mature

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.